Date: 2017-09-20
Type of information: Development agreement
Compound: antibody drug conjugates (ADC) for difficult-to-treat cancers
Company: Glythera (UK) Iontas (UK)
Therapeutic area: Cancer - Oncology
Type agreement: development - collaboration
Action mechanism: antibody drug conjugate (ADC)
Disease: difficult-to-treat cancers.
Details:
- • On September 20, 2017, Glythera and Iontas, a leader in services and platform technologies associated with the discovery and optimisation of fully human antibody drugs, announced a collaboration for the development of ADCs for difficult-to-treat cancers. As part of the agreement, Iontas will generate novel, fully human antibodies against specified targets for proof-of-concept studies. Glythera will have an option for exclusive, worldwide rights to resulting antibodies for the development of ADCs alongside its proprietary conjugation platform, PermaLink® and its in-house portfolio of novel toxins.
- The two companies will select and optimise multiple undisclosed antibodies for ADC development with Glythera exercising its option right to exclusively develop and commercialise the resulting antibodies in ADC formats. Glythera will continue to evaluate numerous ultra-potent ADC-relevant toxin classes, including novel and known mechanisms, with an intention to nominate its first clinical ADC candidate by 2019.
- Iontas will utilize its unique antibody discovery services and bespoke phage display libraries for antibody discovery. Glythera will subsequently generate PermaLink-based ADCs which have been shown to provide a near-100% improvement in tolerability when compared with maleimide-based ADCs in in-vivo models, as well as enhanced tumour cell-killing and an overall improvement in tumour response in xenograft models. The inherent stability of PermaLink permits the use of ultra-potent toxins for ADCs with enhanced efficacy and safety
Financial terms:
- Iontas will receive undisclosed development and clinical milestone payments on each of the ADCs. Glythera will be responsible for the development, manufacturing and commercialisation of any ADC products resulting from the agreement.
Latest news:
Is general: Yes
